Literature DB >> 12894133

Etanercept: An overview.

Ben Goffe1, Jennifer Clay Cather.   

Abstract

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12894133     DOI： 10.1016/mjd.2003.554

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  30 in total

Review 1.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

Review 2.  Safety of etanercept in psoriasis: a critical review.

Authors:  Jose L Sánchez Carazo; Laura Mahiques Santos; Vicente Oliver Martinez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis.

Authors:  Xiao-Xiang Chen; Qing Dai; An-Bin Huang; Hua-Xiang Wu; Dong-Bao Zhao; Xing-Fu Li; Shao-Xian Hu; Nan-Ping Yang; Yi Tao; Jian-Hua Xu; Lin-Di Jiang; Chun-De Bao
Journal:  Clin Rheumatol       Date:  2012-10-04       Impact factor: 2.980

Review 4.  [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis].

Authors:  G Wozel
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

5.  A Case of Tumor Necrosis Factor-alpha Inhibitors-induced Pustular Psoriasis.

Authors:  Jae-Jeong Park; Seung-Chul Lee
Journal:  Ann Dermatol       Date:  2010-05-18       Impact factor: 1.444

Review 6.  Application of the dermatology life quality index in clinical trials of biologics for psoriasis.

Authors:  Mohammad Khurshid Azam Basra; Sadath Hussain
Journal:  Chin J Integr Med       Date:  2012-04-02       Impact factor: 1.978

7.  Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination.

Authors:  Roberta Brambilla; Jessica Jopek Ashbaugh; Roberta Magliozzi; Anna Dellarole; Shaffiat Karmally; David E Szymkowski; John R Bethea
Journal:  Brain       Date:  2011-09       Impact factor: 13.501

8.  TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats.

Authors:  Ahmed A Elmarakby; Jeffrey E Quigley; John D Imig; Jennifer S Pollock; David M Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-11-07       Impact factor: 3.619

Review 9.  Considerations for combined immune checkpoint modulation and radiation treatment.

Authors:  Steven C Almo; Chandan Guha
Journal:  Radiat Res       Date:  2014-07-08       Impact factor: 2.841

10.  Current concepts in the pathogenesis of psoriasis.

Authors:  Rajeev Patrick Das; Arun Kumar Jain; V Ramesh
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.